Mycrx

MycRx is developing oral, small molecule inhibitors that directly target Myc, oncology's 'mega target'. A key driver of all 'Hallmarks of Cancer', >1M new cancer patients are diagnosed annually with overexpressed Myc protein. MycRx compounds display potent cellular Myc target engagement driving profound transcriptional inhibition & on-target mechanistic profiles, resulting in compelling anti-cancer activity. Ready for Late Lead Optimization, our chemistry is on a clear path to development candidate nomination, underpinned by proprietary structural biology revealing a unique, druggable site, potentially a key breakthrough in drugging Myc. Originally based in Melbourne, Australia, MycRx closed a Series A US-led venture capital round and has restructured as a Delaware corporation, with a growing North American Management team.